마이크로바이옴 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global microbiome market size is expected to reach USD 7.88 Billion in 2034 from USD 1.46 Billion in 2025, growing at a CAGR of 20.61 during 2026-2034.This market is experiencing rapid growth as scientific research increasingly highlights the role of microbiomes in human health, agriculture, and environmental applications. Growing understanding of the relationship between microbial communities and disease prevention is driving investments in microbiome-based products and therapies. Rising demand for personalized healthcare solutions and advanced diagnostics is supporting market expansion. Significant research funding is further accelerating innovation across multiple sectors.

Pharmaceutical, biotechnology, and nutrition companies are actively developing microbiome-targeted therapeutics, probiotics, and diagnostic solutions. Advances in genomic sequencing and bioinformatics technologies are enabling deeper insights into microbial ecosystems. Increasing awareness regarding gut health and preventive healthcare is contributing to growing consumer interest. Collaborative research efforts between academic institutions and industry participants are also strengthening market development.

Future opportunities remain substantial as microbiome science continues evolving. Expansion into precision medicine, agricultural productivity enhancement, and environmental sustainability applications will broaden market potential. Technological advancements will improve product development and commercialization capabilities. Continued investment in research and innovation will support long-term market growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

• Bacteria
• Archaea
• Viruses
• Other Microbiomes

By Product

• Therapeutics
• Diagnostics

By Technology

• Genomics
• Proteomics
• Metabolomics

By End-Use

• Infectious Diseases
• Gastrointestinal Disorders
• Metabolic Disorders
• Cancers
• Other Diseases

COMPANIES PROFILED

• Seres Therapeutics, Enterome Bioscience, Ferring Pharmaceuticals, Vedanta BioSciences, Second Genome Inc., Microbiotica, Rebiotix Inc, Locus Biosciences, Osel Inc., Xbiome Co. Ltd, Microba Life Sciences, Biome Australia, Shoreline Biome, Leucine Rich Bio Pvt Ltd, BugSpeaks

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL MICROBIOME MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Bacteria Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Archaea Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Viruses Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Other Microbiomes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL MICROBIOME MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Therapeutics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Diagnostics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL MICROBIOME MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Technology
• 6.2. Genomics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Proteomics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Metabolomics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL MICROBIOME MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Gastrointestinal Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Metabolic Disorders Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Cancers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Other Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL MICROBIOME MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Type
  • 8.2.2 By Product
  • 8.2.3 By Technology
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Type
  • 8.3.2 By Product
  • 8.3.3 By Technology
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Type
  • 8.4.2 By Product
  • 8.4.3 By Technology
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Type
  • 8.5.2 By Product
  • 8.5.3 By Technology
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Type
  • 8.6.2 By Product
  • 8.6.3 By Technology
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL MICROBIOME INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Seres Therapeutics
  • 10.2.2 Enterome Bioscience
  • 10.2.3 Ferring Pharmaceuticals
  • 10.2.4 Vedanta BioSciences
  • 10.2.5 Second Genome Inc
  • 10.2.6 Microbiotica
  • 10.2.7 Rebiotix Inc
  • 10.2.8 Locus Biosciences
  • 10.2.9 Osel Inc
  • 10.2.10 Xbiome Co. Ltd
  • 10.2.11 Microba Life Sciences
  • 10.2.12 Biome Australia
  • 10.2.13 Shoreline Biome
  • 10.2.14 Leucine Rich Bio Pvt Ltd
  • 10.2.15 BugSpeaks